RFK Jr. advocates for regulated peptide market amid FDA safety concerns

Health Secretary Robert F. Kennedy Jr. is advocating for a regulated marketplace for peptides, aiming to expand access by allowing pharmacies to produce these drugs under FDA enforcement discretion.

Kennedy acknowledged on Fox News that the peptides being considered have not been approved by the FDA as safe or effective but emphasized that Americans will purchase them regardless. He stated that the Trump administration is working to ensure access to peptides that are safe and produced in inspected factories.

The FDA has submitted an "Interim Access Policy" on peptides for White House review, which would allow the agency to exercise discretion in enforcing current restrictions on certain peptide drugs. This could provide assurance to specialty pharmacies eager to produce peptides.

FDA scientists have expressed concerns that these peptides lack sufficient study to establish safety and efficacy. Despite this, the proposal seeks to permit compounding pharmacies to produce popular peptides like BPC-157, promoted for muscle building and injury healing.

The proposal has sparked controversy, with the Center for Science in the Public Interest urging the FDA to disregard recommendations from a committee that includes members with ties to peptide-related businesses. This committee recommended lifting restrictions despite FDA scientists' concerns.

The peptide market has gained popularity among wellness influencers and is estimated to be worth $2 billion to $3 billion. The FDA's new policy could temporarily allow compounding pharmacies to produce certain peptides.